anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A remedy for pancreatolithiasis dissolving pancreatic calculus exising in the ductus pancreaticus, having remedying effect on pancreatolithiasis, containing trimethadione or dimethadione well-known as a remedy for petit mal of epilepsy as an active ingredient. CONSTITUTION:A remedy for pancreatolithiasis containing trimethadione or dimethadione as an active ingredient. Pancreatic calculus occurs during the course of chronic pancreatitis, especially alcoholic chronic pancreatitis, develops pancreatitis, and reduces secretion function in the interior and exterior of the pancrease. This time, the fact that dimethadione has dissolving action on pancreatic calculus, and is useful as a remedy for pancreatilithiasis is newly found. Although trimethadione has no directly dissolving action on pancratic calculus, it is demethylated in the organism, converted into dimethadione and useful as a remedy for pancreatilithiasis. A dose of trimethadione is 1-2g/day by oral medication. Dimethadione is preferably applied by intravenous medication.
PURPOSE:To prepare the titled antibiotic substance exhibiting cytopathic effect to Yoshida sarcoma cell, by culturing a bacterial strain belonging to Sretptomyces genus and capable of producing the titled antibiotic substance. CONSTITUTION:A microbial strain belonging to Streptomyces genus and capable of producing an antibiotic substance, RK-1339, e.g. Streptomyces sp. RK-1339 (FERM-P No.6939) is cultured, and the objective antibiotic substance RK-1339 is separated from the cultured product. The substance exhibits the cytopathic effect to Yoshida sarcoma cell, and inhibits the growth of Chlorella bulgaris. It is expected to be useful as an anti-tumor agent.
Phase 1b will include two parts, dose escalation phase (Cohort A) followed by a dose expansion phase (Cohort B). Phase 2 (Cohort C) will evaluate the chosen dose in patients with advanced gastric cancer.
By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study visits where they have give blood samples, answer survey questions, and use a wearable device. After study visits are complete, there is a 4-year follow-up period. Research team will check regular doctor visits and look at participants' medical records.

The purpose of this research is to gather information about the physical, mental, and social health of study participants to help the research team identify factors that put older men with prostate cancer at greater risk for developing serious side effects during hormone therapy. This study is for individuals who are over the age of 65 and plan to receive hormone therapy as part of standard treatment for their prostate cancer. Participants will receive androgen deprivation therapy as part of their standard care with their doctor outside of this study. No drugs or treatments will be given in this study. Participants will instead fill out questionnaires, provide blood samples, and wear a smartwatch paired to a mobile application downloaded to the their personal smartphone or a phone/tablet provided by the research team. This application will help the research team collect information about each study participants' levels of function, general health, physical activity, body composition, memory, mood and side effects during hormone therapy. By collecting this information, doctors leading the study ultimately hope to learn new ways to potentially improve treatment options for older men with prostate cancer while lowering their risks for serious side effects.
The present invention relates to an improved method for the specific production of unsaturated .omega.-3 fatty acids and a method for the production of triglycerides having an increased content of unsaturated fatty acids, in particular .omega.-3 fatty acids having more than three double bonds. The invention relates to the production of a transgenic organism, preferably a transgenic plant or a transgenic microorganism, having an increased content of fatty acids, oils or lipids having .DELTA. 6 double bonds due to the expression of a .DELTA. 6-desaturase from Primulaceae. The invention additionally relates to expression cassettes containing a nucleic acid sequence, a vector and organisms containing at least one nucleic acid sequence or an expression cassette. The invention further relates to unsaturated fatty acids and triglycerides having an increased content of unsaturated fatty acids and use thereof.
Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
The present invention discloses a compound calcium preparation whose main component contains a calcium preparation used as a carrier. The effective dose of other macroelements, especially compounds, such as acetate of trace elements, etc., are added. In the formulation of the present invention, the content of the calcium preparation is controlled to be from 50 to 99.5%. After the compound calcium preparation of the present invention is taken, calcium can be complemented in a high efficiency mode, and simultaneously, other macroelements, especially trace elements can be complemented in a high efficiency mode. Therefore, various chronic diseases caused by deficiency of the elements can be prevented. The present invention is good for health and longevity of a human body.
Implantable and/or wearable medical data acquisition devices (30) associated with an individual, each having NFC communication capability, collect medical data. Each device has a unique identifier. The medical data are read from the devices via a secure link by an NFC reader or transceiver (26) in a wireless communication system mobile station (10) having a unique identifier. The medical data are selectively transmitted via a secure link from the mobile station to a Presence and Group Management (PGM) server (32, 34) configured to manage data services for medical groups. Secure access to the medical data by medical professionals is restricted accordingto a policy system (36). Encryption keys are managed on a group basis by a group key management server (32), assigning the medical data acquisition devices (30) and mobile station (10) to groups based ontheir unique identifiers. The PGM server (32, 34) may send alerts and/or information to the user via the mobile station (10).
Total ring depopulation is sometimes used as a management strategy for emerging infectious diseases in livestock, which raises ethical concerns regarding the potential slaughter of large numbers of healthy animals. We evaluated a farm-density-based ring culling strategy to control foot-and-mouth disease (FMD) in the United Kingdom (UK), which may allow for some farms within rings around infected premises (IPs) to escape depopulation. We simulated this reduced farm density, or "target density", strategy using a spatially-explicit, stochastic, state-transition algorithm. We modeled FMD spread in four counties in the UK that have different farm demographics, using 740,000 simulations in a full-factorial analysis of epidemic impact measures (i.e., culled animals, culled farms, and epidemic length) and cull strategy parameters (i.e., target farm density, daily farm cull capacity, and cull radius). All of the cull strategy parameters listed above were drivers of epidemic impact. Our simulated target density strategy was usually more effective at combatting FMD compared with traditional total ring depopulation when considering mean culled animals and culled farms and was especially effective when daily farm cull capacity was low. The differences in epidemic impact measures among the counties are likely driven by farm demography, especially differences in cattle and farm density. To prevent over-culling and the associated economic, organizational, ethical, and psychological impacts, the target density strategy may be worth considering in decision-making processes for future control of FMD and other diseases.
Atrial Fibrillation (AF) is a common arrhythmia with a prevalence of 1.5-2%. This prevalence increases significantly after 80 years of age. In the presence of the Arrhythmia the risk of stroke increases five fold while the congestive heart failure and the mortality rates are increasing significantly also.After the appearance of first episode(s) some of the patients will present frequent arrhythmia recurrences moving from the paroxysmal status to the persistent and the permanent status of the continuous spectrum of the natural time course of AF. In contrast some other will not present further relapses. To study and predict the dynamic evolution of AF is clinically important, furthermore, the detection of different sub populations risk for AF relapses will determine and different therapeutic approaches. The study will include \> 500 patients 30-80 years old. Inclusion criteria is one up to five paroxysmal AF (PAF) episodes during the last three years. Patients during screening must maintaining Sinus Rhythm. Exclusion criteria are substrate of severe valvular diseases, congenital heart disease, previous heart surgery, hyperthyroidism, severe diseases of the autonomic nervous system, alcoholism, diseases affecting seriously the survival and absence of adequate cooperation for the study. Screening will include 12 lead surface digital ECG, 30 min High Resolution (1000 Hz) ECG recording from 3 pseudo orthogonal x,y,z leads system, and complete ECHO study (2D, PWD, TDI, Strain).Among other indices will be analyzed: P duration, P index, P dispersion, P wave signal for Late potentials, for Wavelets, PQ/RR Dynamics, Heart Rate Dynamics and various markers for the autonomic nervous system status.Primary end point is one or more PAF relapse(s) during a period of 12 months after recruitment in study.Secondary end point is permanent AF during a period of 36 months after recruitment in study.
In preclinical studies three novel anticonvulsants have been studied. The administration of tiagabine did not decrease ethanol consumption in rodents (Schmitt et al., 2002; Rimondini et al., 2002). In a study with alcohol preferring mice topiramate reduced alcohol consumption in a two bottle choice prolonged access model of drinking (Gabriel and Cunningham, 2005). In a study done at our laboratory both topiramate and zonisamide were found to have similar effects on reducing the consumption of ethanol in Wistar rat (Knapp et al., 2004). More recently we found that zonisamide administration decreased alcohol consumption in a limited access model in the C57BL/B6 mouse. These results suggest that zonisamide might be useful as a medication for the treatment of alcohol dependence.

Topiramate and zonisamide have some structural similarities with a sulfamate or methane-sulfonamide containing chain respectively attached to cyclic structure. These structural similarities may explain some of their pharmacological similarities including blockade of voltage sensitive sodium channels and low potency inhibition of carbonic anhydrase (Taverna et al., 1999; Dodgson et al., 2000; Schaf et al., 1987; Masudaet al., 1993). Both topiramate and zonisamide promote weight loss (McElroy et al., 2003; McElroy et al., 2004; Gadde et al., 2003). This effect may be a result of neuromodulation of the regulation of alcohol and food shared by these drugs.
Diabetic foot ulcers are a serious complication of uncontrolled diabetes, emphasizing the need to develop wound healing strategies that are not only effective but also biocompatible, biodegradable, and safe. We aimed to create biomatrices composed of semi-interpenetrated polymer networks of collagen, polyurethane, and dextran, to enhance the wound healing process. The hydrogels were extensively characterized by various analytical techniques, including analysis of their structure, crystallinity, thermal properties, gelation process, reticulation, degradation, cell proliferation, and healing properties, among others. Semi-interpenetrated hydrogels containing dextran at levels of 10%, 20%, and 30% exhibited porous interconnections between collagen fibers and entrapped dextran granules, with a remarkable crosslinking index of up to 94% promoted by hydrogen bonds. These hydrogels showed significant improvements in mechanical properties, swelling, and resistance to proteolytic and hydrolytic degradation. After 24 h, there was a significant increase in the viability of several cell types, including RAW 264.7 cells, human peripheral blood mononuclear cells, and dermal fibroblasts. In addition, these hydrogels demonstrated an increased release of interleukin-10 and transforming growth factor-beta1 while inhibiting the release of monocyte chemotactic protein-1 and tumor necrosis factor-alpha after 72 h. Furthermore, these hydrogels accelerated the wound healing process in diabetic rats after topical application. Notably, the biomaterial with 20% dextran (D20) facilitated wound closure in only 21 days. These results highlight the potential of the D20 hydrogel, which exhibits physicochemical and biological properties that enhance wound healing by inhibiting inflammation and fibrillogenesis while remaining safe for application to the skin.
PURPOSE:To obtain a sanitary composition for peripheral parts of the anus and pudenda, containing an alcohol, a water-insoluble ingredient and a hydrophilic surfactant at a specific weight ratio, capable of instantaneously forming a homogeneous and stable emulsion by charging thereof into water and improved in adsorbability on mucous membranes. CONSTITUTION:A composition is obtained by containing an alcohol (e.g. ethanol, propanol or isopropanol) as an ingredient (A) and a water-insoluble ingredient [e.g. a water-insoluble drug effect agent such as water-insoluble vitamins (A, E, D, etc.) and derivatives thereof and an oil such as olive oil, almond oil, jujube oil, lanolin or turtle oil] as an ingredient (B) at >=1 weight ratio of the ingredients [(A)/(B)] and a hydrophilic surfactant (e.g. anionic, cationic, amphoteric and nonionic surfactants) as an ingredient (C).
Objective: The purpose of this study was to explore the clinical benefits of establishing an enteral nutrition (EN) pathway via percutaneous transhepatic cholangiography drainage (PTCD) catheterization in patients with late-stage malignant obstructive jaundice (MOJ).Methods: We selected 30 patients diagnosed as having late-stage MOJ with malnutrition. A dual-lumen biliary-enteral nutrition tube was placed via PTCD along with a biliary stent implantation. Postoperative EN was provided, and we observed the time taken for tube placement, its success rate, complications, and therapeutic efficacy.Results: Tube placement was successful in all 30 patients with an average procedural time of 5.7 ± 1.4 min with no tube placement complications. Compared to preoperative measures, there was a significant improvement in postoperative jaundice reduction and nutritional indicators one month after the procedure (p < 0.05). Post-placement complications included tube perileakage in 5 cases, entero-biliary reflux in 4 cases, tube blockage in 6 cases, tube displacement in 4 cases, accidental tube removal in 3 cases, and tube replacement due to degradation in 8 cases, with tube retention time ranging from 42 to 314 days, averaging 124.7 ± 37.5 days. All patients achieved the parameters for effective home-based enteral nutrition with a noticeable improvement in their quality of life.Conclusion: In this study, we found that the technique of establishing an EN pathway via PTCD catheterization was minimally invasive, safe, and effective; the tube was easy to maintain; and patient compliance was high. It is, thus, suitable for long-term tube retention in patients with late-stage MOJ.
PROBLEM TO BE SOLVED: To obtain an agent for accelerating shrinkage of collagen useful as an agent for improving the sagging and springiness of the skin and an anti- aging agent by including a whey extract, hydrolyzed casein, 1- acyllysophospholipid and an extract of a plant of the genus Bupleurum. SOLUTION: The objective agent contains one or more components selected from (A) a whey extract, (B) hydrolyzed casein, (C) a 1-acyllysophospholipid of formula I (R1 is an 11-18C saturated fatty acid residue or an 18C fatty acid residue containing 1 to 3 unsaturated double bonds; M is H or an alkali metal) or formula II (R2 is a 13-18C saturated fatty acid residue or an 18C fatty acid residue containing 1 to 3 unsaturated double bonds) and (D) an extract of a plant belonging to the genus Bupleurum (e.g. Bupleurum falcatum Linne and Bupleurum chinese DC.). The component D is obtained by selecting a part expected to contain saikosaponin and saikogenin (e.g. the root part) and separating the component from the selected part e.g. by solvent extraction. These components are preferably included in an amount of 0.0001-20 wt.% expressed in terms of dried solid.
Patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. Patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.
The trial is designed as a patient and assessor-blinded, randomized, controlled trial with two parallel groups. Participants are randomized 1:1 to either ASAD and glenohumeral arthroscopy (intervention group) or glenohumeral arthroscopy alone (control group). The two groups are subscribed identical postoperative rehabilitation consisting of 3 months physiotherapy in a municipally setting. The primary endpoint is the Shoulder Pain and Disability Index (SPADI) 12 months after surgical intervention. The study will adhere to the CONSORT guidelines.

All participants will be recruited consecutively from the outpatient clinic, Arthroscopic Center, Copenhagen University Hospital, Hvidovre. Consultant orthopedic surgeons will conduct the initial eligibility screening as part of their consultation. Eligible participants will be provided with thorough verbal and written information about the trial and their right to withdraw at any time. Patients given their written, informed consent to participate in the trial, will receive scheduled appointments for the baseline examination.
A solid pharmaceutical composition having a coating which disintegrates rapidly in aqueous media is characterised in that the coating comprises an inner layer (A) 0.005 to 1.0 mm. thick of a non-toxic polyalkylene glycol soluble in water and volatile organic solvents and an outer layer (B) less thick than the inner layer, i.e. 0.003 to 0.05 mm. and consisting of a non toxic, water-insoluble, film-forming thermoplastic substance soluble in a volatile organic solvent.  It is preferred that the inner layer be 0.05 to 0.3 mm. thick.  Polyethylene glycols of molecular weight 4000 to 20,000 are preferred for the inner layer.  The outer layer may be composed of cellulose acetate, cellulose acetate phthalate, cellulose acetate succinate, cellulose propionate, cellulose butyrate, a polyalkylmethacrylate, polyvinylacetate a silicone resin, shellac, zein, an acrylic/methacrylic acid copolymer, a vinyl acetate/meleic acid copolymer or a vinyl acetate/vinyl pyrrolidone copolymer.  In the examples, a tablet core of ascorbic acid, succinic acid and ferrous sulphate with excipients is coated with a solution of (A) in a volatile organic solvent followed by (B) in a volatile organic solvent such as chloroform and acetone or ethanol and acetone. Pills, granules and suppositories may also be coated in a similar manner.  Dyestuffs pigments and titanium dioxide may be present in the tablets.
The safety and effectiveness of budesonide delayed-release capsules have been established in pediatric patients 8 to 17 years of age who weigh more than 25 kg for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon. Use of budesonide delayed-release capsules in this age group is supported by evidence from adequate and well controlled studies of budesonide delayed-release capsules in adults, with additional data from 2 clinical studies in 149 pediatric patients treated up to 8 weeks and one pharmacokinetic study in 8 pediatric patients [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)]. 

The observed safety profile of budesonide delayed-release capsules in pediatric patients is consistent with its known safety profile in adults and no new safety concerns were identified [see Adverse Reactions (6.1)]. 

The safety and effectiveness of budesonide delayed-release capsules have not been established in pediatric patients less than 8 years of age for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon.

The safety and effectiveness of budesonide delayed-release capsules have not been established in pediatric patients for the maintenance of clinical remission of mild to moderate Crohn’s disease. An open-label study to evaluate the safety and tolerability of budesonide delayed-release capsules as maintenance treatment in pediatric patients aged 5 to 17 years was conducted, and did not establish the safety and efficacy of maintenance of clinical remission.

Systemic corticosteroids, including budesonide delayed-release capsules, may cause a reduction of growth velocity in pediatric patients. Pediatric patients with Crohn’s disease have a 17% higher mean systemic exposure and cortisol suppression than adults with Crohn’s disease [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].
Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents. The one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents may be delivered together with the direct factor Xa inhibitor and/or direct factor IIa inhibitor or separately from the direct factor Xa inhibitor and/or factor IIa inhibitor.